-
2013
Asamedic was established by Per Erik Stribolt-Halvorsen, Geir Ivar Westen and Tore Ritter Westen. Stribolt-Halvorsen was personally motivated after losing both his father and brother to heart attacks and commenced research to find a way to reduce mortality from heart attacks
-
2015
The company commenced full operations. It received positive feedback from patent authorities on feasibility study and delivered a patent application resulting in patent pending status word-wide. Series 1 Funding Round of MNOK 3.9
-
2016
First prototype produced. Asamedic received funds from Innovation Norway and was approved SkatteFunn-status by The Research Council of Norway. The firm became a member of the Norwegian Medical Association. Patent pending on two new applications
-
2017
Series 2 Funding Round, MNOK 15. Very positive dissolution test after R&D on solvent. Asamedic elects new board of directors and establishes Advisory Board
-
2018
External marketing analysis conducted, with very positive results showing high market acceptance and willingness to purchase. 6,000 vials set in stability program
-
2019
Application for marketing authorization.
Patent application moves from patent pending status to patent granted in Australia. Generation II container development started with Inventas and NTNU. Marketing Application submitted for Coxor in December 2019
-
2020
Enter partnership with ELC and Convex to conduct clinical trial on Coxor with new methodology to reveal important clinical data on ASA behavior. 18 months stability data shows positive outcome. Initiates dialogue with potential industry partners
-
2021
Reaches end of DCP procedure January 19th with positive outcome. Completes national phase for Norway and Denmark and receives local Marketing Authorizations. In addition, OTC status is achieved.
-
2022
Positive article from clinical trial published. Asamedic out-licenses rights of Coxor® in the Nordics to Evolan Pharma AB. Coxor will be launched in the near future, with Norway being the first market.
-
2023
Coxor launched in Norway in February 2023 with great success. Feedback for authorities, media and KOLs very positive.
-
2024
Asamedic initiates own outreach to potential licensing partners. Attends CPHI Milano in October with own booth, resulting in >100 companies interested in licensing Coxor for various parts of the world.